Simulations Plus, Inc. (SLP): Results of Operations and Financial Condition
Simulations Plus, Inc. (SLP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 slp-2026531xexx991x263.htm EX-99.1 Document Exhibit 99.1 Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results RESEARCH TRIANGLE PARK, NC, July 9, 2026 – Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-
How this was made
The 30-second read
Why it matters
The earnings section provides a near-term fundamental check (revenue growth, margin, net income vs prior-year loss), while the merger agreement introduces a separate, time-sensitive catalyst tied to expected closing in Q4 calendar 2026.
Market read
Traders can update both operating expectations from the Q3 print and deal-risk/valuation assumptions from the newly disclosed definitive acquisition agreement.
What to watch
The filing does not provide deal economics or detailed closing conditions here, so traders may need to wait for the full merger agreement terms and any regulatory or financing contingencies.
Background
This is an SEC Form 8-K (Item 2.02) with a press release covering Q3 FY2026 results and a merger update disclosed as of June 15, 2026.
Ticker impact
Simulations Plus reported Q3 FY2026 results with revenue up 7% to $21.9M and disclosed a definitive merger agreement with Altaris.
Near-term repricing is plausible as traders weigh improved operating performance versus merger closing and integration risk.
The article provides specific quarterly and nine-month financial figures plus a new, time-stamped definitive merger agreement disclosed in the same 8-K.
Market effects
Reinforces demand for model-informed and AI-accelerated drug development software and services, while highlighting ongoing consolidation risk in the niche.
Limited; company is US-based and the disclosure is deal- and results-specific.
Moderate; drug development tooling is globally used, but the news is primarily company-specific.
Counterpoint
Services growth and gross margin improvement may be less durable than the market assumes, and deal execution risk could dominate the stock reaction.
Key entities
- public_companySimulations Plus, Inc.
Nasdaq-listed model-informed and AI-accelerated drug development software and services provider reporting Q3 FY2026 results and a definitive merger agreement.
- acquirerAltaris, LLC
Buyer via affiliates in the definitive merger agreement disclosed in the filing.
